A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether minimally invasive mitral valve surgery (MIMVS) should be considered as an alternative to conventional sternotomy (ST) in high-risk patients. Eightysix papers were found by a systematic search, of which seven were comparing MIMVS with ST in high-risk patients and addressing the clinical question. Five were retrospective observational and two were propensity-matched studies. One paper included patients with infective endocarditis, one with preoperative renal failure, two papers the elderly, three papers compared redo surgery. Author, journal, date, patient group, country of publication, relevant outcomes, results and study weaknesses were tabulated. In total, these seven studies included 1254 high-risk patients (n = 523 MIMVS, 731 ST) undergoing mitral valve surgery, either repair or replacement. End-points of interest were mortality, intraoperative and postoperative outcomes and survival. With regard to MIMVS group, in-hospital mortality was lower in three studies and with no statistically significant differences in the other four; cardiopulmonary bypass (CPB) times were similar in one study, but were longer in three other studies. MIMVS led to reduced postoperative complications in six studies (one did not report complications); among studies that included late mortality, one reported better survival in the MIMVS group whereas the other two did not report differences. We conclude that, although MIMVS may be associated with longer CPB and cross-clamp times, it is at least as safe as ST in terms of both mortality and morbidity, in these high-risk groups.
INTRODUCTION
A best evidence topic was written according to a structured protocol. This protocol is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 75-year old female is admitted in accident and emergency department with pulmonary oedema. Past medical history includes previous double CABG. Bedside echo shows severe mitral regurgitation with ruptured chordae and suspicion of vegetation. After stabilization, she is transferred to the cardiac catheterization laboratory, and the coronary angiogram shows patent left internal mammary artery to left anterior descending artery and vein graft to right coronary artery. As the cardiac surgeon on-call, you are asked to consider her for surgery at a certain point, and your trainee asks whether MIMVS rather than sternotomy (ST) would provide better outcomes in this high-risk patient. Kaplan-Meier estimates showed faster rates of independent ambulation (P = 0.039) and independent sit-to-stand activity (P = 0.003) in the MIMVS group; No differences in time to independent stair climbing (P = 0.31)
No readmission rate differences at 1 year (P = 0.54) MIMVS resulted in significant lower mortality rate than ST Limitations:
Mixed group with minimally invasive aortic valve without the possibility to separate outcomes of interest for mitral rather than mortality
Continued
RESULTS
All studies (but one which did not report separate outcomes for mitral surgery) concluded that MIMVS in high-risk patients led to reduced postoperative complications. In terms of mortality, MIMVS was comparable with ST. Mihos et al. [2] retrospectively compared 22 MIMVS and 28 ST patients with infective endocarditis (IE). There were no differences in terms of baseline characteristics; chronicity of IE and disease burden were also similar in both groups. Mean CPB and crossclamp time were longer in the MIMVS group (P = 0.001). There were no differences in terms of in-hospital mortality in between groups (P = 0.25). MIMVS group had fewer postoperative composite complications (41 vs 75%, P = 0.02), decreased incidence of sepsis (0 vs 21%, P = 0.02), less use of intraoperative blood products (59 vs 93%, P = 0.004), higher mitral valve repair rate (55 vs 25%, P = 0.03), shorter intensive care unit (ICU) length of stay (56 vs 114 h, P = 0.009), whereas there was no difference in survival rate at 2.5 years.
Tang et al. [3] in a propensity-matched study compared outcomes of 180 patients with chronic renal disease. Mortality was 20% lower in the MIMVS group (P = 0.037). Postoperative complications were also lower, such as acute renal failure (10 vs 21%, P = 0.05), stroke (1 vs 9%, P = 0.017), pacemaker insertion (3 vs 11%, P = 0.044) and chest tube outputs (503 vs 1333 ml, P < 0.001).
Iribarne et al. [4] reported outcomes in 75 patients above 75 years old, among them 70 were MIMVS and 105 ST. Minimally invasive technique was associated with prolonged cross-clamp and bypass time (P = 0.037 and 0.001) but with 3.1-day shorter MIMVS was performed safely and efficiently in patients with prior cardiac surgery and advantages include fewer red blood cell and blood product transfusions, as well as decreased intubation time and length of hospital stay Limitations:
Retrospective study and there was a trend towards older patients and a significantly lower preoperative ejection fraction in the MIMVS group although more urgent operations were performed in the redo ST group BEST EVIDENCE TOPIC hospitalization (P = 0.033); there were no differences in terms of rate of major postoperative complications or long-term survival; however, MIMVS led to a lower cost of hospitalization (P = 0.007) and more common discharge to home, faster rates of independent ambulation (P = 0.039) and independent sit-to-stand activity (P = 0.003), although there were no differences in time to independent stair climbing (P = 0.31). There was no difference in terms of readmission rate at 1 year (P = 0.31) and in terms of long-term survival (P = 0.60) between groups. Holzhey et al. [5] in a propensity-matched study analysed outcomes of 286 patients with age >70 (143 MIMVS vs 143 ST). MIMVS led to longer duration of surgery (P = 0.01), cardiopulmonary bypass (P = 0.0001) and cross-clamp time (P = 0.0015). There were no differences with regard to 30-day mortality (P = 0.82) or combined major adverse cardiac and cerebrovascular events (P = 0.86). The incidence of arrhythmias and pacemaker implants was higher in ST group (P = 0.023 and P = 0.059, respectively).
Sharony et al. [6] conducted an observational study in 270 patients with previous cardiac surgery, 100 and 177 were MIMVS and ST, respectively; mortality for MIMVS was significantly lower than ST (P = 0.004), other outcomes were amalgamated with minimally invasive aortic valve surgery, hence were not reported.
In a retrospective analysis, Bolotin et al. [7] compared 38 MIMVS and 33 ST mitral patients who had previous cardiac surgery. There was similar operative mortality in both groups (P = 0.976), similar cardiopulmonary bypass, operating room and ICU times, but shorter postoperative intubation time (P = 0.008), reduced blood transfusion requirements (P = 0.001) and reduced length of hospital stay in the MIMVS group (P = 0.001).
Burfeind et al. [8] performed a retrospective analysis on 60 and 155 MIMVS and ST mitral patients, respectively, who had previous cardiac surgery. In-hospital mortality was 0/60 (0%) vs 21/155 (14%), red cell transfusion was 3 ± 4 vs 12 ± 12 units, chest tube output was 352 ± 361 vs 1683 ± 3939 ml whereas cardiopulmonary bypass times were 208 ± 76 vs 157 ± 53 min for MIMVS and ST groups, respectively.
CLINICAL BOTTOM LINE
MIMVS has acceptable short-and long-term results in patients at high risks such as those who have undergone redo surgery, the elderly, those with renal impairment and IE. Despite the heterogeneous populations included, we conclude that MIMVS is at least as safe as conventional ST in these high-risk patient groups.
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